I don't disagree that some changes are needed in Metabolic's management, but a wholesale management housecleaning is not needed, and would probably only make things worse.
They need to persevere with ACV1, which I always saw as a drug with potential equal to or better than AOD9604, and managment needs to work hard to get a partnership in place.
At the moment and probably for the next two months, this stock will be a huge bargain. It may be possible to pick up the stuff at near 10 cents before April is out. May and June should be mildly positive in anticipation of the sciatica study. But, with positive results out of the sciatica study in June, you will see the stock price triple from present levels by the end of July.
Longer term, nothing will cure but a partnership with a big pharma. The sooner the better.
Add to My Watchlist
What is My Watchlist?